A year ago today, the U.S. FDA approved glofitamab for the treatment of relapsed or refractory #DLBCL. In this podcast episode, Krish Patel, of Providence Swedish Cancer Institute Research, joins chadi nabhan MD, MBA, FACP to outline clinical trial data for this bispecific antibody. 🎧 buff.ly/4cGqUGJ

Dr. Fengting Yan Providence Swedish publishes in Nature Medicine on a novel KAT6 inhibitor for advanced #breastcancer nature.com/articles/s4159… 👏👏

Dr. Charles Cobbs Providence Swedish Cancer Institute Research publishes on overcoming treatment escape in glioblastoma: science.org/doi/full/10.11…

Dr Jed Gorden Providence Swedish Cancer Institute Research publishes on increasing access to #screening for #lungcancer in CHEST journal.chestnet.org/article/S0012-… #prevention 🩻🫁

Dr. Jed Gorden also publishes on reducing health disparities in #lungcancer link.springer.com/article/10.100…

Amazing Thoracic Oncology session with Dr. Diane Tseng (UW Medicine/Fred Hutch Cancer Center), @AngelQinMD (Michigan Medicine), & Dr. Siddhartha Devarakonda (Providence Swedish) here at #BestofASCO24 📍Seattle!

Using AI deep learning to help understand cancer risk over time: no impact on vitamin D supplements on breast cancer risk using radiographic measures #swog academic.oup.com/jncics/advance…

Providence Swedish Cancer Institute Research researchers study rising incidence of #angiosarcoma in the United States in collaboration with Dana-Farber Cleveland Clinic Duke University Fred Hutch Cancer Center and others. JAMA Network Open jamanetwork.com/journals/jaman…

Dr. Krish Patel contributes to national guidelines on bispecific antibodies which are available at Providence Swedish in both #clinicaltrials and as #standardofcare Providence Swedish Cancer Institute Research ashpublications.org/blood/article/…

Sunshine Gray presents on nursing experience with #tarlatamab at the oncology nursing society congress. So glad for the critical efforts of our RNs on our research team and the recent FDA approval of this #bispecific for #smallcelllungcancer ons.confex.com/ons/2024/meeti…

Navigating Neoadjuvant vs Adjuvant Immunotherapy Approaches in NSCLC Requires Further Elucidation Providence Swedish Cancer Institute Research #lcsm #oncology #MedTwitter onclive.com/view/navigatin…

Sid Devarakonda, MD, expands on the significance of OS data when evaluating a treatment for efficacy in NSCLC and noted the potential value of additional end points including pCR and EFS. Providence Swedish Cancer Institute Research #lcsm #oncology #MedTwitter onclive.com/view/clinical-…

Please join us in welcoming our incoming class of physician #residents. Our residency program is known for its innovative learning environments, delivering on the Providence Mission and training our future physicians. #ProvidenceSwedish #ProvidenceSwedishEverett #WSU

Struggling to juggle your daily tasks while keeping your energy levels up? It's time to focus on energy conservation for a better quality of life! Sonja Braasch, OTR/L, senior occupational therapist, shares how you can save #energy for the things you love and need to do. 💪💡

Dr. Devarakonda Providence Swedish Cancer Institute Research participates in a study of new #targetedtherapy for #lungcancer #nsclc jtd.amegroups.org/article/view/8… 🫁

Dr. Krish Patel Krish Patel works with docs Test Account and OHSU Knight Cancer Institute to make #carT therapy for #lymphoma more patient friendly and cost-effective through #outpatient delivery link.springer.com/article/10.100…

Dr. Aliea Herbert studies #cancerrehab in improving #survivorship after #HSCT with colleagues Emory University Mayo Clinic MD Anderson Cancer Center pubmed.ncbi.nlm.nih.gov/38912164/

Dr. Dubard-Gault cancer geneticist and preventionist Providence Swedish Cancer Institute Research Providence Swedish presents a rare cancer syndrome due to a newly described variant in JCO Precision Oncology: ascopubs.org/doi/10.1200/PO…

Dr. Swathi Namburi Providence Swedish Cancer Institute Research coauthors a clinical trial in Journal of Clinical Oncology of new #bispecific antibody for #myeloma #immunotherapy ascopubs.org/doi/10.1200/JC…

Tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage #SCLC (DeLLphi-303): a multicentre, phase 1b study Presented today IASLC #WCLC2025, 5 pm CEST thelancet.com/journals/lanon… Providence Swedish Cancer Institute Research